Guidance Capital Inc. purchased a new stake in Indivior PLC (NASDAQ:INDV – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 21,543 shares of the company’s stock, valued at approximately $782,000.
A number of other hedge funds also recently made changes to their positions in INDV. Two Seas Capital LP lifted its stake in shares of Indivior by 5.5% in the third quarter. Two Seas Capital LP now owns 3,671,072 shares of the company’s stock worth $131,608,000 after acquiring an additional 191,579 shares during the period. Assenagon Asset Management S.A. raised its holdings in Indivior by 129.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,540,344 shares of the company’s stock worth $126,921,000 after purchasing an additional 1,999,416 shares during the last quarter. Newtyn Management LLC bought a new position in Indivior during the 2nd quarter worth approximately $53,577,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Indivior in the 2nd quarter worth approximately $14,781,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Indivior in the 2nd quarter worth approximately $7,988,000. 60.33% of the stock is currently owned by institutional investors.
Indivior Price Performance
Indivior PLC has a one year low of $27.68 and a one year high of $42.81. The company’s 50 day simple moving average is $34.90 and its two-hundred day simple moving average is $35.62. The company has a market cap of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84.
Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.06 by $0.26. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. The company had revenue of $356.00 million for the quarter, compared to analysts’ expectations of $329.35 million. Research analysts anticipate that Indivior PLC will post 3.66 EPS for the current year.
Indivior Dividend Announcement
The company also recently declared a special dividend, which was paid on Friday, November 6th. Stockholders of record on Friday, October 30th were issued a dividend of $8.13 per share. The ex-dividend date was Tuesday, November 3rd.
Insider Activity at Indivior
In other news, CAO Woodrow D. Anderson purchased 1,500 shares of Indivior stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average price of $35.69 per share, with a total value of $53,535.00. Following the completion of the transaction, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. The trade was a 5.74% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.74% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of research firms have recently commented on INDV. Wall Street Zen lowered shares of Indivior from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. Barclays lifted their target price on shares of Indivior from $43.00 to $45.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Craig Hallum restated a “buy” rating and issued a $53.00 target price on shares of Indivior in a report on Tuesday, August 4th. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Finally, Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Indivior presently has a consensus rating of “Buy” and a consensus target price of $46.40.
Read Our Latest Research Report on Indivior
Indivior Company Profile
Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.
The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.
Featured Articles
- Five stocks we like better than Indivior
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV – Free Report).
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
